Septerna (NASDAQ:SEPN) Issues Quarterly Earnings Results

Septerna (NASDAQ:SEPN) announced its quarterly earnings results on Monday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15), FiscalAI reports. The firm had revenue of $18.88 million during the quarter, compared to analysts’ expectations of $20.78 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%.

Septerna Price Performance

Shares of NASDAQ:SEPN traded up $1.89 during trading hours on Monday, hitting $50.74. The company’s stock had a trading volume of 713,677 shares, compared to its average volume of 365,581. The firm’s fifty day moving average price is $39.52 and its 200 day moving average price is $32.59. Septerna has a 52 week low of $17.98 and a 52 week high of $51.10. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of -93.96 and a beta of 2.20.

Insider Buying and Selling

In other news, SVP Daniel Long sold 3,333 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total transaction of $126,087.39. Following the transaction, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,647,265.96. This trade represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Elizabeth Bhatt sold 25,000 shares of Septerna stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $7,665,196. The trade was a 12.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 32,333 shares of company stock worth $1,375,727. Insiders own 5.80% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on SEPN shares. JPMorgan Chase & Co. raised their price objective on Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, August 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Thursday, October 15th. Raymond James Financial reiterated a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a report on Tuesday, August 11th. Wells Fargo & Company increased their price target on Septerna from $50.00 to $61.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. Finally, Stifel Nicolaus set a $49.00 price target on Septerna in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.22.

About Septerna

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development.